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Background
It is important to show efficacy in allergic rhinitis (AR)
patients regardless of symptom severity since most AR
patients presenting to a doctor have moderate-to-severe
disease.
Objective
To assess the efficacy of MP29-02* (a novel intranasal for-
mulation of azelastine hydrochloride [AZE] and fluticasone
propionate [FP]) compared to AZE, FP or placebo nasal
sprays in seasonal AR (SAR) patients according to severity.
Methods
610 patients (>= 12 years old) with moderate-to-severe SAR
were randomized into a double-blind, placebo-controlled,
14-day, parallel-group trial to receive MP29-02*, commer-
cially-available AZE or FP nasal sprays or placebo (all given
as 1 spray/nostril bid; total daily dose: 548 µg AZE; 200 µg
FP]). The primary efficacy variable was change from base-
line in rTNSS (AM + PM). This primary endpoint was
assessed post-hoc according to symptom severity. All
patients had moderate-to-severe disease. Patients were
categorized into two severity groups according to their
median baseline rTNSS. Those with a baseline rTNSS >
18.9 points were defined as more severe and those with a
baseline rTNSS <= 18.9 points were defined as less severe.
Results
MP29-02* was significantly superior to either FP or AZE
in alleviating patients’ rTNSS regardless of disease severity.
For those patients with less severe disease (<=18.9) MP29-
02* reduced the rTNSS from baseline by -4.68 compared
to -3.21 for FP (Diff: -1.46; 95% CI -2.68, -0.25; p=0.0188),
-2.41 for AZE (Diff: -2.26; 95% CI -3.42, -1.10; p=0.0002)
and -1.16 for placebo (Diff: -3.51; 95% CI: -4.78, -2.24;
p<0.0001), corresponding to a relative treatment difference
of 42% vs FP and 64% vs AZE. Patients with more severe
disease (>18.9) experienced a -6.24 point reduction in
their rTNSS with MP29-02*, significantly more than -4.73
with FP (Diff: -1.52; 95% CI -2.99, -0.04; p=0.0436), -4.11
with AZE (Diff: -2.13; 95% CI: -3.55, -0.71; p=0.0035) and
-3.18 with placebo (Diff -3.06; 95% CI -4.34, -1.77;
p<0.0001). For these more severe patients, the relative
treatment effect was 49% to FP and 70% to AZE.
Conclusion
MP29-02* provided benefits for all patients, offering signif-
icantly greater relief from nasal symptoms compared to
two firstline therapies regardless of disease severity and is
the drug of choice for the treatment of AR.
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